It is the case of HCC, for which after almost two decades of clinical use, RTKi have lost first position to the combined immunotherapy using anti-PDL1 plus either anti-VEGFR or anti-CTLA4. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.